
    
      NS-018 will be self-administered orally at a dose of 300 mg BID. The BAT will be administered
      according to manufacturer's instructions and Investigator discretion. Subjects will complete
      study visits at Screening, Day 1 and Day 15 of Cycle 1, 2, 3, 4, 5, 6 and Day 1 of every
      cycle thereafter. At these visits, blood/urine sampling, spleen measurements, bone marrow
      assessments, patient-reported outcome (PRO) assessments, and safety assessments may be
      performed.
    
  